Ivan Inigo

Publications by Year

Research Areas

Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, Monoclonal and Polyclonal Antibodies Research, Cell death mechanisms and regulation, Immune Cell Function and Interaction

Most-Cited Works

• → Discovery of N-(2-Chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a Dual Src/Abl Kinase Inhibitor with Potent Antitumor Activity in Preclinical Assays(2004)1,285 cited
• → Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade(2018)363 cited
• → Dasatinib (BMS-354825) Pharmacokinetics and Pharmacodynamic Biomarkers in Animal Models Predict Optimal Clinical Exposure(2006)149 cited
• → Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft(2005)85 cited
• → Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity(2020)68 cited
• → Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels(2006)62 cited
• → Multivalent Scaffold Proteins as Superagonists of TRAIL Receptor 2–Induced Apoptosis(2013)57 cited
• BMS-354825 potently inhibits multiple selected oncogenic tyrosine kinases and possesses broad-spectrum antitumor activities in vitro and in vivo(2005)
• → Ixabepilone (BMS-247550) plus trastuzumab combination chemotherapy induces synergistic antitumor efficacy in HER2 dependent breast cancers and is accompanied by modulation of molecular response markers(2005)32 cited
• → Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054(2018)30 cited